Merck and Moderna announced Phase 3 results for a personalized mRNA vaccine, Intismeran Autogene, given alongside the immunotherapy drug Pembrolizumab to 1,137 high-risk melanoma patients after tumor removal surgery. Over an average 24.6-month follow-up, the combination reduced recurrence or death risk by 42% and metastasis risk by 38% compared with Pembrolizumab alone, with 82.2% of combination-treatment patients remaining recurrence-free versus 70% on Pembrolizumab alone.
wired.com
· 2026-10-24
Merck and Moderna released full results from a trial of their personalized mRNA melanoma vaccine earlier than planned, after details apparently leaked. The companies reported that 82% of patients who received the vaccine alongside Keytruda remained cancer-free two years later.
gizmodo.com
· 2026-10-23
A phase III trial of 1,137 melanoma patients found that intismeran, a personalized mRNA vaccine developed by Moderna and Merck, reduced the risk of cancer recurrence or death by 42% when given alongside an immunotherapy drug after tumour-removal surgery. The companies released key results early after trial data leaked online ahead of their scheduled presentation at a European oncology conference in Madrid on 24 October.
nature.com
· 2026-10-23
Moderna and Merck announced that their personalized mRNA melanoma vaccine, combined with Merck's Keytruda, reduced the risk of death or cancer recurrence by 42% compared to Keytruda alone in a Phase 3 trial of 1,137 patients with stage IIB-IV melanoma. The companies released top-line results early after an oncology news outlet broke an embargo ahead of a scheduled presentation at the European Society of Medical Oncology conference in Madrid, with full data set for publication in the New England Journal of Medicine.
arstechnica.com
· 2026-10-22
GoKawiil